Arrowhead Pharmaceuticals Inc to Present Topline Data from the Phase 2 SEQUOIA Study Transcript
Hi, everybody. Thanks for joining us today. We are here to talk about the Fazirsiran SEQUOIA top line results and give an outline for what the Phase III looks like. So thanks all for joining us this early in the morning. Next slide, please.
Just before we start, I want to make sure everybody knows that we will be making forward-looking statements, so please refer to our SEC filings for the risk factors.
Next slide. Today on the panel, we have Dr. Virginia Clark from the University of Florida, who's going to talk about AAT and natural history of the disease as well as some of the significance of the findings from the SEQUOIA study. Myself, I'm Vince Anzalone, the Vice President of Investor Relations; and Javier San Martin, our Chief Medical Officer.
Next slide. So today, we -- as I mentioned, Javier is going to speak about the Fazirsiran SEQUOIA top line results. Dr. Clark will then provide some context about why this is important. Javier will go back into the Phase III design, and then we'll give some
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
